Core Viewpoint - The company, Xianle Health, aims to enhance its global strategy by issuing H-shares and listing on the Hong Kong Stock Exchange to strengthen its capital and competitive position [1] Group 1 - The company plans to deepen its global strategic layout by leveraging international capital market advantages [1] - The issuance of H-shares is intended to create a diversified capital operation platform [1] - The goal is to improve the company's capital strength and overall competitiveness [1] Group 2 - The initiative is expected to accelerate the development of the company's overseas business [1] - The company aims to establish a complete domestic and international dual circulation pattern [1] - This move is designed to consolidate the company's position within the industry [1]

Group 1 - The core viewpoint of the article is that Xianle Health (300791.SZ) plans to issue overseas listed foreign shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to enhance its global strategy and capital strength [1] Group 2 - The company aims to leverage the advantages of international capital markets to create a diversified capital operation platform [1] - The initiative is intended to accelerate the development of overseas business and improve the domestic and international dual circulation pattern [1] - This move is expected to strengthen the company's competitive position within the industry [1]

Core Viewpoint - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [1] Group 1 - The fourth meeting of the fourth board of directors is scheduled for January 8, 2026, to review the proposal for issuing H-shares [1] - The initiative aims to leverage international capital market advantages to improve the company's capital strength and overall competitiveness [1] - The company is currently in discussions with relevant intermediaries regarding the issuance and listing details, which are not yet finalized [1]